for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eyegate Pharmaceuticals Inc

EYEG.OQ

Latest Trade

3.36USD

Change

-0.13(-3.72%)

Volume

7,759

Today's Range

3.30

 - 

3.45

52 Week Range

2.25

 - 

9.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.49
Open
3.45
Volume
7,759
3M AVG Volume
0.51
Today's High
3.45
Today's Low
3.30
52 Week High
9.60
52 Week Low
2.25
Shares Out (MIL)
3.05
Market Cap (MIL)
10.63
Forward P/E
-1.79
Dividend (Yield %)
--

Latest Developments

More

Eyegate Announced Reverse Stock Split Of Shares Of Co's Common Stock At A Ratio Of 1-For-15

Eyegate Pharma Receives Approval From FDA To Initiate PE Pilot Study

EyeGate Pharmaceuticals Reports Qtrly Earnings Per Share $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eyegate Pharmaceuticals Inc

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry

Biotechnology & Drugs

Contact Info

271 Waverley Oaks Rd Ste 108

+1.781.7889043

http://www.eyegatepharma.com/

Executive Leadership

Paul G. Chaney

Chairman of the Board

Stephen From

President, Chief Executive Officer, Director

Sarah M. Romano

Chief Financial Officer

Michael Manzo

Vice President - Engineering

Steven J. Boyd

Director

Key Stats

Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-22.650

2017

-13.950

2018

-4.500

2019(E)

-1.950
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.54
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-53.17
Return on Equity (TTM)
-44.18

Latest News

BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel

* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL

BRIEF-EyeGate Pharmaceuticals Says On May 15, Board Increased Size To Eight From Seven

* EYEGATE PHARMACEUTICALS INC - ON MAY 15, BOARD INCREASED SIZE OF BOARD FROM SEVEN DIRECTORS TO EIGHT DIRECTORS - SEC FILING Source http://bit.ly/2KuxceA Further company coverage:

BRIEF-Eyegate Pharmaceuticals Posts Q1 Revenue Of $1.096 Million

* EYEGATE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13

* ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING

BRIEF-Eyegate Announces $11.25 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK

BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology

* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment

* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:

BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln

* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:

BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery

* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY

BRIEF-Eyegate Promotes Sarah Romano To CFO

* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage:

BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment

* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

BRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000

* Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update

BRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study

* Eyegate Pharma enrolls first patient in phase 2b clinical study of EGP-437 for cataract surgery Source text for Eikon: Further company coverage:

BRIEF-Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc

* Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 Source text: (http://bit.ly/2sM4eCk) Further company coverage:

BRIEF-Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals

* Innoven Partenaires S.A. reports a 9.5 percent stake in Eyegate Pharmaceuticals Inc as of June 14 - SEC filing

BRIEF-Empery Asset Management reports 9.22 pct passive stake in Eyegate Pharmaceuticals

* Empery Asset Management LP reports a 9.22 percent passive stake in Eyegate Pharmaceuticals Inc as of June 9, 2017 - SEC filing Source text: (http://bit.ly/2saWqql) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up